About this Research Topic
The tumor microenvironment comprises tumor and stromal cells, immune cells, blood and lymphatic vessels, and dense extracellular matrix that provide a suitable milieu for the evolution of advanced malignancies. Soluble tumor-associated signaling molecules control tumorigenesis and tumor progression. Among soluble mediators, chemotactic factors, also known as chemoattractants, exert pro- or anti-tumorigenic functions by (i) directly regulating tumor cell proliferation and invasive capacity; (ii) recruiting immune cells, and/or (iii) modulating angiogenesis / vasculogenesis. The chemoattractant family includes a structurally heterogeneous group of molecules (e.g. Chemerin, C5a, LTB4 etc.) as well as the more homogeneous family of chemokines. Chemoattractant receptors are heptahelical transmembrane cell surface receptors typically coupled to G proteins and are best known for their ability to promote leukocyte trafficking. Stimuli produced within the tumor microenvironment affect the expression and/or function of chemoattractants, which in turn regulate tumor growth via cell-specific receptor signaling.
This Research Topic aims to gather a series of articles related to basic research on chemoattractants and translational studies investigating chemoattractants as druggable molecules in experimental tumor models. We welcome the submission of Reviews, Mini-Reviews and Original Research articles covering the following topics:
1. Molecular mechanisms regulating chemoattractant/receptor expression in the tumor microenvironment.
2. Characterization of the role of chemoattractants in the regulation of primary tumor growth and of metastasis.
3. Regulation of tumor angiogenesis/vasculogenesis by chemoattractants.
4. Modulation of chemoattractants as a mechanism of tumor immune evasion.
5. Role of chemoattractants in intratumor recruitment and localization of immune effector cells.
6. Activation or inhibition of chemoattractant signaling in experimental cancer immunotherapy.
Keywords: Chemoattractant, Tumor microenvironment, Chemokine, Cancer immunotherapy